Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by MyoKardia

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Bristol-Myers Squibb

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2021

            Details:

            The NDA submission was based on the results of the pivotal Phase 3 EXPLORER-HCM trial, which evaluated mavacamten in patients with symptomatic oHCM versus placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million

            Deal Type: Acquisition November 17, 2020

            Details:

            Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2020

            Details:

            Mavacamten treatment resulted in favorable effect on cardiac structure -- significantly reduced hypertrophy in patients with hypertrophic cardiomyopathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: American College of Cardiology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 11, 2020

            Details:

            MyoKardia and American College of Cardiology reported establishment of a nationwide registry of hypertrophic cardiomyopathy. The registry will support MyoKardia’s post-marketing safety and effectiveness study of mavacamten.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million

            Deal Type: Acquisition October 05, 2020

            Details:

            The acquisition provides Bristol Myers Squibb access to Mavacamten, a potential first-in-class myosin inhibitor with compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.